Amgen Sponsors QB3@953 Incubator For Life Science Startups Jun 22, 2016 06:00PM
Amgen Appoints Esteban Santos Executive Vice President, Operations Jun 17, 2016 04:00PM
Amgen (AMGN) Announces FDA Advisory Committee Meeting for ABP 501 Jun 13, 2016 04:01PM
Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab Jun 13, 2016 04:00PM
Amgen (AMGN) Announces Results from Post-Hoc Analysis of Pivotal Phase 3 ASPIRE Study Jun 10, 2016 04:02PM
View Older Stories

Jun 10, 2016 04:00PM New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
Jun 10, 2016 02:30AM BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Jun 8, 2016 04:32PM Amgen (AMGN) Announces Erenumab Phase 2 Met Primary Endpoint in Chronic Migraine Prevention
Jun 8, 2016 04:30PM Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
Jun 7, 2016 09:00AM New National Survey Sheds Light On How To Better Engage Students In Science Education
Jun 6, 2016 04:02PM Amgen (AMGN) Announces Presentation of Kyprolis Phase 3 Data in Relapsing Multiple Myeloma; Improved PFS, ORR Noted
Jun 6, 2016 04:00PM New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen
Jun 3, 2016 04:15PM Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers
Jun 3, 2016 04:00PM Amgen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
May 27, 2016 07:30AM Amgen (AMGN) Announces Receipt of Positive EMA CHMP Opinion on Kyprolis as Relapsed Multiple Myeloma Treatment
May 27, 2016 07:21AM Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
May 26, 2016 04:01PM Amgen (AMGN) Kyprolis Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript
May 26, 2016 04:00PM Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"
May 19, 2016 06:02PM Amgen Announces Voting Results of Annual Meeting of Stockholders
May 19, 2016 04:36PM Amgen (AMGN) Will Present BLINCYTO, Kyprolis, Aranesp, and Nplate Data at EHA 2016
May 19, 2016 04:34PM Amgen Highlights Data To Be Presented At 21st Congress Of The European Hematology Association
May 18, 2016 05:10PM Amgen (AMGN) Says Data to be Presented at ASCO Shows Insights Into Treatment Options For Patients
May 18, 2016 05:05PM Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients
May 17, 2016 04:00PM Amgen's Breakaway from Cancer® Public Service Announcement Delivers Message That Education, Resources And Hope Are Essential In The Fight Against Cancer
May 11, 2016 06:57AM Amgen (AMGN) Teams with NFL Legend Joe Montana for New 'Breakaway from Heart Disease' Campaign
May 11, 2016 06:45AM Hall of Fame Quarterback Joe Montana and Amgen Team Up to Launch Breakaway from Heart Disease™ to Make Heart Health a Priority
May 9, 2016 09:15AM Platelet BioGenesis Wins Amgen Golden Ticket For LabCentral
May 6, 2016 04:00PM Amgen To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
May 3, 2016 04:22PM Amgen's (AMGN) BLINCYTO sBLA Granted FDA Priority Review as Treatment of Certain ALL
May 3, 2016 04:21PM FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Apr 28, 2016 04:01PM Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
Apr 25, 2016 05:30PM Amgen Announces Webcast Of 2016 First Quarter Financial Results
Apr 25, 2016 09:00AM Amgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer
Apr 19, 2016 04:01PM Amgen (AMGN) Says Study in The Lancet Shows Nplate Significantly Increases Durable Platelet Response
Apr 19, 2016 04:00PM Nplate® (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia
Apr 3, 2016 12:17PM Amgen (AMGN) Announces Publication of Positive Repatha Phase 3 GAUSS-3 Data
Apr 3, 2016 09:05AM Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
Apr 1, 2016 04:01PM Amgen (AMGN), UCB Phase 3 Data Comparing Romosozumab With Teriparatide Presented at ENDO
Apr 1, 2016 04:00PM Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
Mar 21, 2016 04:01PM Amgen (AMGN) Says 19 Abstracts Will be Presented at ACC
Mar 21, 2016 04:00PM Amgen To Present Repatha® (Evolocumab) Data At ACC.16
Mar 21, 2016 06:22AM Amgen (AMGN), UCB Announce Romosozumab Phase 3 Met Primary Endpoint in Men With Osteoporosis
Mar 21, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Mar 16, 2016 02:02PM Amgen (AMGN) Comments Following Repatha Patent Win
Mar 16, 2016 02:00PM Amgen Wins Patent Case On Repatha® (Evolocumab)
Mar 16, 2016 12:33PM Regeneron (REGN) and Sanofi Confirm Negative Praluent Ruling, 'Strongly Disagree' with Verdict (AMGN)
Mar 10, 2016 04:00PM Amgen (AMGN) sBLA for Exapnded Enbrel Use Accepted by FDA
Mar 10, 2016 04:00PM FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis
Mar 3, 2016 04:00PM Amgen To Present At The Cowen And Company 36th Annual Health Care Conference
Mar 2, 2016 04:15PM Amgen Announces 2016 Second Quarter Dividend
Mar 1, 2016 04:01PM Amgen (AMGN) Submits sBLA For BLINCYTO
Mar 1, 2016 04:00PM Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)
Feb 22, 2016 06:21AM Amgen (AMGN), UCB Announce FRAME Phase 3 Met co-Primary Endpoints; One Secondary Endpoint Missed
Feb 22, 2016 01:00AM Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Feb 16, 2016 06:50AM Amgen (AMGN) Announces Aranesp Phase 3 Met Primary Endpoint in MDS Red Blood Cell Transfusion Reduction
View Older Stories